Document is current
Any future updates will be listed below
-
Authors
Subramanian, Ajay https://orcid.org/0000-0001-7892-886X
Su, Shengqin https://orcid.org/0000-0002-6946-8256
Flerlage, Jamie https://orcid.org/0000-0002-4182-9355
Alig, Stefan https://orcid.org/0000-0001-6825-702X
Younes, Sheren
Marks, Lianna J.
Pinnix, Chelsea
Vega, Francisco https://orcid.org/0000-0001-5956-452X
Steiner, Raphael
Kumar, Priya https://orcid.org/0000-0001-8945-6917
Mocikova, Heidi
Sykorova, Alice
Prochazka, Vit https://orcid.org/0000-0002-9861-3117
Milito, Cristiane
Allen, Pamela
Paulino, Darina
Ramsay, Alan
Flerlage, Timothy
Palese, Monica https://orcid.org/0000-0002-2624-0868
West, Robert
Zhu, ChunFang
Noordenbos, Troy https://orcid.org/0000-0003-0583-4584
Schroers-Martin, Joseph https://orcid.org/0000-0003-4128-2537
Zhao, Shuchun
Park, Natalie J.
Kalbasi, Anusha https://orcid.org/0000-0001-8692-1457
Moding, Everett J. https://orcid.org/0000-0001-7913-5351
Newman, Aaron M. https://orcid.org/0000-0002-1857-8172
Advani, Ranjana H.
Hoppe, Richard T. https://orcid.org/0000-0003-0125-0194
Diehn, Maximilian https://orcid.org/0000-0003-2032-0581
Natkunam, Yasodha https://orcid.org/0000-0002-9816-1018
Alizadeh, Ash A. https://orcid.org/0000-0002-5153-5625
Binkley, Michael Sargent https://orcid.org/0000-0002-2640-5255
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA266824)
- License Information
-
More Information
Article History
Received: 18 April 2025
Accepted: 11 August 2025
First Online: 26 September 2025
Competing interests
: H.M. reports consulting and honoraria with Lilly, Bristol-Myers Squibb, Abbvie, and Roche. M.D. reports research funding from AstraZeneca, Genentech, Varian Medical Systems and Illumina, ownership interest in CiberMed and Foresight Diagnostics, consultancy from AstraZeneca, Boehringer Ingelheim, BMS, Genentech, Gritstone Oncology, Illumina, Regeneron and Roche, and multiple issued and pending patents including patents licensed to Foresight Diagnostics and Roche. A.A.A. reports consultancy for Celgene, Chugai, Genentech, Gilead, Janssen, Pharmacyclics and Roche, scientific advisory board membership in the Lymphoma Research Foundation, and Professional Affiliations with the American Society of Hematology, American Society of Clinical Oncology, American Society of Clinical Investigation, Leukemia & Lymphoma Society, Research Funding from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the US National Institutes of Health, Celgene, BMS and Pfizer, patent filings including patent issued, licensed and with royalties paid from FortySeven, a patent pending and Licensed to Foresight, a patent pending relating to MARIA, a patent issued and licensed to CiberMed, a patent issued and a patent pending to CiberMed, patents issued to Idiotype Vaccines, and a patent issued, licensed and with royalties paid from Roche, and equity ownership interests in CiberMed Inc., ForeSight Diagnostics, FortySeven Inc. and CARGO Therapeutics. The remaining authors declare no competing interests.
